NIH Record - National Institutes of Health

Unique Population

COLBOS Study Reveals Mysteries of Alzheimer’s Disease

A smiling Quiroz stands at podium in Lipsett Amphitheater
Dr. Yakeel T. Quiroz

Photo:  Lisa Helfert

A Colombian family with a rare mutation for early-onset Alzheimer’s Disease has provided researchers a unique opportunity to study the disease years before symptoms begin, said Dr. Yakeel T. Quiroz, during the recent Florence Mahoney Lecture on Aging, part of the Wednesday Afternoon Lecture Series.

By identifying the preclinical stages of the disorder, researchers hope to “delay the clinical onset and prevent Alzheimer’s disease and dementia altogether,” said Quiroz, associate professor in the departments of psychiatry and neurology at Massachusetts General Hospital and Harvard Medical School.

As a college student, more than 20 years ago, she began studying together with Prof. Francisco Lopera an extended family group of 6,000 people in Antioquia, Colombia. Many of them carry a rare, genetic mutation for early-onset AD, called the Presenilin-1 (PSEN1) mutation. Carriers develop the disease with almost 100 percent certainty. On average, they experience cognitive impairment at age 45 and dementia at age 50. 

Quiroz has followed individuals from these families who are destined to develop AD and dementia decades before they show symptoms. “We have a window of opportunity to characterize some of the earliest preclinical changes,” she noted. 

Image
Quiroz stands at podium. Beside her, a slide of a boy feeding his father and a map of South America. The slide reads: A large extended family with early-onset Alzheimer's Disease in Antioquia, Colombia.
In Lipsett Amphitheater, Quiroz discusses COLBOS, a collaborative, longitudinal biomarker study launched in 2014 involving the Universidad de Antioquia, Colombia, and Massachusetts General Hospital, Boston.

Photo:  Lisa Helfert

There are several clinical, cognitive and biomarker similarities between early-onset AD and sporadic late-onset AD, the more common form of the disease. Age, family history and heredity are the most important risk factors for late-onset AD, Quiroz said. Most people diagnosed with late-onset AD are over 65 years of age. 

Those with the PSEN1 mutation undergo brain changes years before they begin to exhibit symptoms, she said. In children, boys with the mutation had decreased working memory compared to girls with the mutation. This suggests a “sex-specific genetic risk” in early-life cognitive abilities. Brain abnormalities, such as changes in brain activation and brain volume, begin as young as age 9. 

“The increased risk of cognitive abilities in boys may have important implications when we’re thinking about learning and academic achievement,” Quiroz said. 

Quiroz stands in Clinical Center garden next to bust of Florence Mahoney.
Quiroz visits the Mahoney memorial located in a northside patio of the Clinical Center. Florence Stephenson Mahoney (1899–2002) devoted much of her life to advocating for creation of the National Institute on Aging.

Photo:  Lisa Helfert

In 2014, Quiroz launched COLBOS (Colombia-Boston), a collaborative, longitudinal biomarker study between the Universidad de Antioquia, Colombia, and Massachusetts General Hospital, Boston. Every 2 years, Colombians from the PSEN1 families travel to the United States, where doctors collect health data and perform advanced neuroimaging examinations. 

COLBOS has shown that the amyloid protein begins accumulating in carriers around age 28, Quiroz said. The protein clumps together to form plaques that build up between neurons. Amyloid is one of two proteins—the other tau—that accumulate in the brains of patients with AD.  

The tau protein starts accumulating in their late 30s, Quiroz explained. This occurs a few years before they exhibit symptoms. Tau forms threads and tangles together, which disrupts brain connectivity. Increased levels of tau only occur in parts of the brain where amyloid was present. It’s linked to memory decline. 

“The accumulation of amyloid appears to be a steady process, beginning as early as 20 years before dementia onset,” she explained. “In contrast, tau pathology is very rapid.”

There are two blood biomarkers that might help researchers detect AD before symptoms begin. Carriers of the mutation have a higher concentration of neurofilament light chain (NfL) and ptau217. Both are proteins. These blood biomarkers might allow individuals who don’t have access to tau or amyloid brain imaging an opportunity to get an earlier AD diagnosis, she said. 

Quiroz and Hodes stand holding a plaque presented to her.
NIA director Dr. Richard Hodes presents Quiroz with a framed memento of her lecture.

Photo:  Lisa Helfert

One woman who participated in the COLBOS study carried the PSEN1 mutation. However, she did not develop AD symptoms until she was in her 70s, almost 30 years after the expected age of onset for other carriers. Quiroz said her brain had high levels of amyloid and very low levels of tau. 

Genetic testing revealed the woman had two copies of the APOE Christchurch mutation, which seems to have protected her brain against tau accumulation. Quiroz’s team has developed an antibody that mimics the mutation’s function. Researchers are studying the antibody to determine whether it might be a promising therapeutic. 

“Families with autosomal dominant mutations provide a unique opportunity to study disease progression from preclinical to clinical stages, [and] develop and improve measures for early detection, novel interventions and clinical trials,” Quiroz concluded. 

Mahoney lectures are sponsored by NIA and named in honor of Florence Stephenson Mahoney (1899–2002), who devoted much of her life to successfully advocating for the creation of NIA and increased support for NIH. 

The lecture can be viewed at https://videocast.nih.gov/summary.asp?live=44272.  

The NIH Record

The NIH Record, founded in 1949, is the biweekly newsletter for employees of the National Institutes of Health.

Published 25 times each year, it comes out on payday Fridays.

Associate Editor: Dana Talesnik
Dana.Talesnik@nih.gov (link sends e-mail)

Assistant Editor: Eric Bock
Eric.Bock@nih.gov (link sends e-mail)

Staff Writer: Amber Snyder
Amber.Snyder@nih.gov (link sends e-mail)